Compare GLDD & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | ESPR |
|---|---|---|
| Founded | 1890 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.6M | 898.5M |
| IPO Year | 2006 | 2013 |
| Metric | GLDD | ESPR |
|---|---|---|
| Price | $15.25 | $3.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $20.00 | $6.67 |
| AVG Volume (30 Days) | 917.5K | ★ 5.7M |
| Earning Date | 02-17-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.27 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $834,599,000.00 | $303,802,000.00 |
| Revenue This Year | $13.16 | $27.49 |
| Revenue Next Year | $5.14 | N/A |
| P/E Ratio | $12.88 | ★ N/A |
| Revenue Growth | ★ 12.53 | 2.83 |
| 52 Week Low | $7.51 | $0.69 |
| 52 Week High | $16.72 | $4.18 |
| Indicator | GLDD | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 61.88 | 53.37 |
| Support Level | $14.77 | $3.06 |
| Resistance Level | $16.72 | $3.52 |
| Average True Range (ATR) | 0.64 | 0.22 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 59.13 | 60.89 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.